Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00719017
Recruitment Status : Unknown
Verified April 2013 by Stefano Palomba, University Magna Graecia.
Recruitment status was:  Recruiting
First Posted : July 21, 2008
Last Update Posted : April 8, 2013
Information provided by (Responsible Party):
Stefano Palomba, University Magna Graecia

Brief Summary:

Recent findings have suggested that laparoscopic surgery is safe and effective, as well as laparotomic one, for treating patients with early stage endometrial cancer (ESEC). Moreover, our long-term previous data have shown a trend in vaginal cuff recurrence in subjects who underwent laparoscopic approach to ESEC consisting of extrafascial hysterectomy, bilateral salpingo-oophorectomy, pelvic +/- para-aortic nodes dissections, regardless grading or lymphovascular space invasion.

Based on these considerations, the aim of the current protocol-study will be to compare two different strategies for vaginal cuff recurrences prevention in patients affected by ESEC treated with laparoscopic surgery. In particular, upper vaginectomy followed by observation will be compared to post-operative brachytherapy.

Condition or disease Intervention/treatment Phase
Early Stage Endometrial Cancer Procedure: Upper vaginectomy Radiation: Post-operative brachytherapy Procedure: Standard procedures Phase 4

Detailed Description:

Women with ESEC scheduled for laparoscopic surgery will be enrolled and randomized in three arms [vaginectomy group (VG), brachytherapy group (BG), and control group (CG)]. All laparoscopic procedures will consist of total hysterectomy, bilateral salpingo-oophorectomy, peritoneal washing, systematic inspection of peritoneal cavity and biopsy of each suspect lesion, and pelvic (and eventual para-aortic) lymphadenectomy. In VG an upper vaginecomy will be added to standard laparoscopic procedures followed by observation, whereas BG will receive post-operative brachytherapy. CG will be treated with standard protocol for management of ESEC according to National Comprehensive Cancer Network (

Safety and efficacy data will be recorded in each group for 24 months of follow-up.

Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less will be considered significant.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study.
Study Start Date : September 2007
Estimated Primary Completion Date : December 2013
Estimated Study Completion Date : June 2014

Arm Intervention/treatment
Experimental: Vaginectomy group
Upper vaginectomy
Procedure: Upper vaginectomy
Laparoscopic surgery with upper vaginectomy
Experimental: Brachytherapy group
Post-operative brachytherapy
Radiation: Post-operative brachytherapy
Laparoscopic surgery followed by brachytherapy
Active Comparator: Control group
Standard treatment
Procedure: Standard procedures
Laparoscopic surgery +/- brachytherapy +/- pelvic radiation

Primary Outcome Measures :
  1. Vaginal cuff recurrences [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Post-operative complications [ Time Frame: six months ]
  2. Adverse events [ Time Frame: 24 months ]
  3. Loco-regional recurrence rate [ Time Frame: 24 months ]
  4. Distant recurrence rate [ Time Frame: 24 months ]
  5. Quality of life [ Time Frame: 24 months ]
  6. Overall survival [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Early stage endometrial cancer

Exclusion Criteria:

  • Other pre-malignancies and malignancies
  • Major medical conditions
  • Psychiatric disorders
  • Current or past history of acute or chronic physical illness
  • Premenstrual syndrome (PMS)
  • Current or past (within 6 months from study enrolment) use of drugs influencing cognition, vigilance, and/or mood.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00719017

Contact: Stefano Palomba, MD +39-0961.883234

"Pugliese" Hospital Recruiting
Catanzaro, Italy, 88100
Contact: Ingrid Tomaino, MD    +39 0961 883234   
Sponsors and Collaborators
University Magna Graecia
Principal Investigator: Stefano Palomba, MD Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro
Study Chair: Fulvio Zullo, MD Department of Obstetrics and Gynecology, University "Magna Graecia" of Catanzaro

Responsible Party: Stefano Palomba, Associate Professor, University Magna Graecia Identifier: NCT00719017     History of Changes
Other Study ID Numbers: 03/2007
First Posted: July 21, 2008    Key Record Dates
Last Update Posted: April 8, 2013
Last Verified: April 2013

Keywords provided by Stefano Palomba, University Magna Graecia:
Early stage edometrial cancer
Quality of life

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female